Maze Therapeutics (MAZE) announced the appointment of Herve Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D., who will continue to serve on the Board. He most recently served as CEO of Incyte Corporation (INCY) from 2014 to 2025 and as Chairman of Incyte from 2015 to 2025.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Two new option listings on September 17th
- Maze Therapeutics price target raised to $34 from $19 at Guggenheim
- Maze Therapeutics price target raised to $50 from $34 at H.C. Wainwright
- Maze Therapeutics Advances Clinical Programs Amid Financial Stability
- Maze Therapeutics price target raised to $37 from $30 at BTIG